Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

Inclusion Criteria

• •Aged ≥ 18 years
• •Confirmed diagnosis of myelofibrosis (primary, post-polycythemia vera, or post essential thrombocythemia)
• •Adequate hematologic, renal, and hepatic function
• •Have at least 2 symptoms with an average score ≥ 3 or an average total score of ≥ 10 over the 7-day period prior to randomization using the MFSAF v4.0
• •Prognostic risk-factor score of Intermediate-1 or higher per Dynamic International Prognostic Scoring System (DIPSS) scoring system
• •Spleen volume of ≥ 450 cm\^3
• •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2